The positive interim analysis and low dropout rate increase the probability of Phase 2b success, but the stock is highly binary on fall 2026 top-line results. Traders should monitor enrollment updates and any FDA feedback on the Phase 3 plan. Given the $61M market cap and no revenue, the stock remains speculative with high event risk.
Price Chart
Executive Summary
Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead candidate Halneuron® in chemotherapy-induced neuropathic pain (CINP). The extension follows a positive interim analysis of the ongoing Phase 2b double-blinded trial, which showed a treatment effect versus placebo. The company plans to submit the full data package to the FDA to support a Phase 3 program starting in the first half of 2027, with top-line results from the double-blinded portion expected in fall 2026.
Key Facts
- New 12-week open-label extension study for Halneuron® in CINP has commenced; several patients already enrolled.
- Positive interim analysis of the double-blinded Phase 2b trial supported continuation with 80% power at 210-240 patient sample size.
- Top-line results from the double-blinded Phase 2b study expected in fall 2026.
- Overall study dropout rate under 5%, far below typical chronic pain studies.
- No FDA-approved treatments currently exist for CINP; Halneuron® has Fast Track designation.
- Phase 3 program projected to start in first half of 2027.
- Dogwood is a development-stage biopharma with $61M market cap; no approved products or revenue.
Financial Impact
No financial data disclosed; clinical-stage company with no revenue. Positive interim data and extension study de-risk the pipeline but do not provide immediate financial impact.
Risk Factors
- Phase 2b top-line results in fall 2026 could fail to meet endpoints.
- No approved products or revenue; company is pre-commercial.
- Dependence on single lead candidate Halneuron®.
- Regulatory and clinical execution risks for Phase 3 program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296648 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.12 (+0.00%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.12 (−7.44%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.12 (−7.44%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.12 (+43.43%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.12 (−34.12%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.43%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.43%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.12 (−34.50%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.12 (−62.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers